Phathom Pharmaceuticals, Inc. R&D Expenses

R&D Expenses of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including R&D Expenses growth rates and interactive chart. Research and development (R&D) expenses are associated with the research and development of a company's goods or services. A company generally incurs R&D expenses in the process of finding and creating new products or services. It is an operating expense and can be deducted from a company's income taxes.

Highlights and Quick Summary

  • R&D Expenses for the quarter ending September 29, 2021 was $16.6 Million (a -23.1% decrease compared to previous quarter)
  • Year-over-year quarterly R&D Expenses decreased by -60.13%
  • Annual R&D Expenses for 2020 was $98.1 Million (a 381.73% increase from previous year)
  • Annual R&D Expenses for 2019 was $20.4 Million (a 101770.0% increase from previous year)
  • Twelve month R&D Expenses ending September 29, 2021 was $100 Million (a -8.36% decrease compared to previous quarter)
  • Twelve month trailing R&D Expenses increased by 2.33% year-over-year
Trailing R&D Expenses for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
$100 Million $110 Million $103 Million $98.1 Million
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical R&D Expenses of Phathom Pharmaceuticals, Inc.

Most recent R&D Expensesof PHAT including historical data for past 10 years.

Interactive Chart of R&D Expenses of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. R&D Expenses for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $16.61 $21.6 $20.58
2020 $41.65 $25.77 $14.86 $15.87 $98.15
2019 $12.7 $4.47 $2.77 $0.43 $20.37
2018 $0.01 $0.02

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.